Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | FABP3 | P05413 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972964 | 1.00 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| Water SCHEMBL9702527 | 0.96 | CA2 (0.68) | CA2NFKB1GPR84FABP3CYP3A4 | |
| Zinc Ion SCHEMBL9806605 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| Lithium Ion SCHEMBL11438840 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| Lithium Ion SCHEMBL9781566 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| Potassium Ion SCHEMBL9246555 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| SCHEMBL3438387 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| SCHEMBL9577313 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| SCHEMBL3685429 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 | |
| Lithium Ion SCHEMBL5680426 | 0.96 | CA2 (0.72) | CA2NFKB1GPR84FABP3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016939-B2 | Skin treatment methods and compositions for transdermal delivery of active agents | TOPIX PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-110381917-B | Use of compatible solutes | 默克专利股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116782923-A | Scar treatment composition | 塔普克斯制药公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116710081-A | Scar treatment composition | 塔普克斯制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230190593-A1 | SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS | TOPIX PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-116075310-A | Topical vitamin C compositions | 塔普克斯制药公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4171537-A1 | TOPICAL VITAMIN C COMPOSITION | Topix Pharmaceuticals, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596584-B2 | Skin treatment methods and compositions for transdermal delivery of active agents | TOPIX PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20130115178-A1 | TANNING ENHANCERS AND SELF-TANNING SUBSTANCES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20130108565-A1 | TANNING ENHANCERS AND SELF-TANNING SUBSTANCES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-02 | — | — | US | disclosed |
| US-20130059924-A1 | PHOTOSTABILISERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130058879-A1 | TRIAZINES AS REACTION ACCELERATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130011350-A1 | METAL OXIDE PARTICLES AFTERTREATED WITH ORGANIC PHOSPHORUS COMPOUNDS | SACHTLEBEN CHEMIE GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20120258154-A1 | PARTICULATE UV PROTECTION AGENT | SACHTLEBEN CHEMIE GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| EP-2470174-A1 | USE OF FAA AND ITS DERIVATIVES IN COSMETICS AND DERMATOLOGY | Merck Patent GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120052028-A1 | CINNAMIC ACID ASCORBATES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2011023287-A1 | USE OF FAA AND ITS DERIVATIVES IN COSMETICS AND DERMATOLOGY | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | WO | disclosed |
| US-20100034893-A1 | PARTICULATE UV PROTECTION AGENT | MERCK PATENT GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, PLAT | CA2 3856/4885NFKB1 2079/4885GPR84 594/4885 |
| US-20230190593-A1 | SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS | CUTA, MMP1, TYR | CA2 2211/4885NFKB1 2065/4885GPR84 1798/4885 |
| US-11596584-B2 | Skin treatment methods and compositions for transdermal delivery of active agents | CUTA, MMP1, TYR | CA2 2211/4885NFKB1 2065/4885GPR84 1798/4885 |
| US-20120052028-A1 | CINNAMIC ACID ASCORBATES | PROC, C1S, NISCH | CA2 832/4885NFKB1 362/4885GPR84 3946/4885 |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, MMP2 | CA2 4072/4885NFKB1 1656/4885GPR84 1114/4885 |
| US-20130115178-A1 | TANNING ENHANCERS AND SELF-TANNING SUBSTANCES | DERA, ALDOA, GALE | CA2 2634/4885NFKB1 950/4885GPR84 2664/4885 |
| US-12016939-B2 | Skin treatment methods and compositions for transdermal delivery of active agents | CUTA, MMP1, TYR | CA2 2211/4885NFKB1 2065/4885GPR84 1798/4885 |
| US-20130059924-A1 | PHOTOSTABILISERS | ALDH1A1, ALDH18A1, ALDH1A2 | CA2 1438/4885NFKB1 1676/4885GPR84 2969/4885 |
| US-20130058879-A1 | TRIAZINES AS REACTION ACCELERATORS | TYR, NAT1, TERT | CA2 2970/4885NFKB1 1106/4885GPR84 2101/4885 |
| US-20130011350-A1 | METAL OXIDE PARTICLES AFTERTREATED WITH ORGANIC PHOSPHORUS COMPOUNDS | SOST, PHOSPHO1, PLCG2 | CA2 237/4885NFKB1 1542/4885GPR84 3562/4885 |
| US-20120258154-A1 | PARTICULATE UV PROTECTION AGENT | SOD1, SOD3, UNG | CA2 1877/4885NFKB1 1349/4885GPR84 3548/4885 |
| US-20130108565-A1 | TANNING ENHANCERS AND SELF-TANNING SUBSTANCES | TYR, DERA, HAAO | CA2 3191/4885NFKB1 1837/4885GPR84 2968/4885 |
| US-20100034893-A1 | PARTICULATE UV PROTECTION AGENT | SOD1, SOD3, UNG | CA2 1877/4885NFKB1 1349/4885GPR84 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.